NASDAQ · NXTC
NextCure, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for NXTC: Nov 4, 2026
NextCure, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.9. The reported EPS for the same quarter last year was $-3.22.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.90 | $-0.90 | $-0.90 | 1 |
| Dec 2026 | $-0.79 | $-0.79 | $-0.79 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Fintel · The Motley Fool- RTTNews · Aug 12, 2:26 AM EDTRTW Bio's Avere To Merge With NextCure(RTTNews) – RTW Biotech Opportunities Ltd. (RTW.L) on Wednesday announced that its private portfolio company Avere Therapeutics agreed to merge with NextCure Inc. (NXTC) in an all-stock transaction.
- RTTNews · Aug 10, 9:17 AM EDTNextCure Reports Q2 Loss As Proposed Avere Merger Reshapes Strategic Direction(RTTNews) – NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for cancer, has reported its second-quarter 2026 financial results along with a major business update centered on its proposed merger with Avere The
- RTTNews · Jul 14, 11:18 PM EDTTop Biotech Gainers: NXTC Soars On Merger Deal, BMGL Moves Past Nasdaq Woes, OTLK Awaits FDA Verdict(RTTNews) – Today's top gainers in the biotech space include NextCure, ahead of its planned merger with a private company that will create a newly branded public entity; Basel Medical, which recently regained Nasdaq compliance; and Outlook Therapeutics, which is awaiting an FDA d
- RTTNews · Jul 14, 6:51 AM EDTNextCure And Avere Therapeutics Announce Merger To Advance Oral IL-23 Therapy; Stock Up(RTTNews) – NextCure, Inc. (NXTC) has entered into a definitive all-stock merger agreement with privately-held Avere Therapeutics, Inc., a biotech firm focused on oral therapies for IL-23 driven inflammatory diseases.
- Zacks · Jul 8, 8:33 AM EDT3 Cancer Stocks to Watch as Oncology Innovation AcceleratesOncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.
- Fintel · May 11, 5:01 PM EDTLUCID CAPITAL MARKETS Initiates Coverage of NextCure (NXTC) with Buy RecommendationFintel reports that on May 11, 2026, LUCID CAPITAL MARKETS initiated coverage of NextCure (NasdaqGS:NXTC) with a Buy recommendation. Analyst Price Forecast Suggests 84.63% Upside
- RTTNews · Jan 23, 7:49 AM ESTNext Cure Highlights Progress Across ADC Pipeline As Company Extends Cash Runway Into 2027(RTTNews) – Next Cure Inc. (NXTC) outlined steady clinical and operational momentum across its two antibody-drug conjugate programs while reporting a preliminary year-end cash position that supports operations into the first half of 2027. The update reflects the company's continu
- RTTNews · Nov 12, 1:16 PM ESTNextCure Shares Jump 15% After Private Placement Announcement(RTTNews) – NextCure, Inc. (NXTC) rose 14.88% to $9.61, up $1.24, after announcing it has entered into a private placement of approximately $21.5 million, issuing 2,523,477 shares of common stock or pre-funded warrants at $8.52 per share to healthcare-focused institutional invest
- Zacks · Nov 11, 9:55 AM ESTDoes NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 107.9% in NextCure (NXTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Fintel · Nov 7, 1:49 PM ESTLadenburg Thalmann Upgrades NextCure (NXTC)Fintel reports that on November 7, 2025, Ladenburg Thalmann upgraded their outlook for NextCure (NasdaqGS:NXTC) from Neutral to Buy. Analyst Price Forecast Suggests 81.77% Upside
- The Motley Fool · Aug 7, 11:32 PM EDTNextCure (NXTC) Q2 Loss Widens 71%GAAP net loss per share was $(11.29) for Q2 2025, missing the consensus GAAP EPS estimate of $(4.62) by a wide margin, mainly due to a $17.0 million up-front license fee.
- RTTNews · Jul 25, 6:52 AM EDTNextCure Soars On Encouraging Preclinical Data Of Brittle Bone Disease Drug Candidate(RTTNews) – Shares of NextCure Inc. (NXTC) are up nearly 30% at $6.60 in premarket trading on Friday, following encouraging preclinical data of its brittle bone disease drug candidate, NC605.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for NextCure, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.